USFDA suggests corrective measures to Sun Pharmaceutical’s Mohali facility

The USFDA had classified the inspection as "Official Action Indicated" (OAI).

Sun Pharmaceuticals to acquire minority stake in Agatsa Software and Remidio Innovative Solutions

Agasta Software is engaged in research, development and commercialization of medical devices

Sun Pharmaceutical receives warning letter from USFDA for Halol facility

The Halol facility was placed under Import Alert by USFDA.

Sun Pharmaceutical gets OAI from USFDA for Mohali facility

Sun Pharmaceutical Industries Q1FY22 consolidated PAT soars to Rs. 1408.65 Cr

It posted net loss of Rs.(2429.81) crores for the period ended June 30, 2020.

Sun Pharmaceutical’s internals remain strong: ICICI Securities

US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio

Sun Pharmaceutical Q3FY21 net profit at Rs. 1852.48 Cr

The company has reported total income of Rs.25699.68 crores during the 9 months period ended December 31, 2020.

Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis

ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025

Indian pharma market grew 10.2% yoy in January 2026

Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise

Sun Pharma gets DCGI nod to launch generic Semaglutide injection for weight loss in India

Company to launch product after the expiry of semaglutide patent in India